With the last patient’s 72-week visit now complete in the NATiV3 Phase 3 trial, Inventiva is roughly one data-lock away from knowing whether lanifibranor can challenge a MASH treatment landscape that already has two FDA-approved agents on the board. The 72-week endpoint is not a soft biomarker readout; it is a full histological assessment, and the topline data now sits weeks, not quarters, away. That proximity is the real news here: after years of enrollment, the uncertainty resolves soon.
The strategic pressure is real. Resmetirom and obeticholic acid’s regulatory path reshaped market expectations, and lanifibranor enters that environment as a pan-PPAR agonist with a different mechanistic profile targeting all three PPAR isoforms simultaneously. Its Phase 2b NATIVE data, published in the New England Journal of Medicine, showed meaningful reductions in steatosis-activity-fibrosis scores, which gave NATiV3 its scientific rationale. Whether that mechanism translates into Phase 3 histological endpoints, specifically MASH resolution without fibrosis worsening and fibrosis improvement without MASH worsening, is what this readout will settle. The bar is demanding: resmetirom achieved MASH resolution in 30% of patients at 52 weeks versus 10% on placebo in its pivotal study, a benchmark the field now uses as an informal reference point.
NATiV3 enrolled patients with moderate to advanced fibrosis, a population where durable fibrosis regression matters as much as steatohepatitis resolution. That design choice was deliberate: it positions lanifibranor, if successful, for a patient segment where treatment decisions remain genuinely difficult and where physicians are still calibrating which agents to reach for first. An oral small molecule with a differentiated mechanism would enter formulary negotiations with something to argue about, even in a market that is no longer empty.
The single variable that will define Inventiva’s next twelve months is whether NATiV3 hits both co-primary histological endpoints. A split result, one endpoint cleared and one missed, would create a regulatory conversation the company does not want. Watch the fibrosis endpoint specifically: resolution of steatohepatitis without fibrosis improvement has not been enough to carry a MASH approval, and that precedent is now baked into how regulators evaluate the entire asset class.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
